Trials / Completed
CompletedNCT03053024
Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants
An Observational Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 54 (actual)
- Sponsor
- Xian-Janssen Pharmaceutical Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study (retrospective and prospective) is to describe participant and disease characteristics and treatment pattern of Bortezomib treated mantle cell lymphoma (MCL) participants in China.
Conditions
Timeline
- Start date
- 2017-04-14
- Primary completion
- 2019-09-30
- Completion
- 2019-09-30
- First posted
- 2017-02-14
- Last updated
- 2020-11-06
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03053024. Inclusion in this directory is not an endorsement.